CGEM Q3 2025 Earnings — Cullinan Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CGEMCullinan Therapeutics, Inc.

$894M

Q3 2025 Earnings

Healthcare Medical - Pharmaceuticals

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$56M

Net Income

-$51M

EPS (Diluted)

$-0.86

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$37M

Free Cash Flow

$0

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$484M

Total Liabilities

$33M

Stockholders' Equity

$451M

Cash & Equivalents

$103M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$56M	-$49M	-13.8%
Net Income	-$51M	-$41M	-24.8%